Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MR-130A-01 Transdermal patch, 130A-01 patch, 130A-01 contraceptive patch, containing norelgestromin
MR-130A-01 · 2 trials · 1 indication
A responder is a subject with no ovulation. A responder is a subject with no ovulation. Ovulation during treatment is defined as a Hoogland-Skouby score 5 or 6 in combination with fulfilment of Landgren criterion.
A responder is a subject with no ovulation. A responder is a subject with no ovulation. Ovulation during treatment is defined as a Hoogland-Skouby score 5 or 6 in combination with fulfilment of Landgren criterion.
| Arm | Type | Description |
|---|---|---|
| "regular": regular application without planned application errors | EXPERIMENTAL | - |
| Extended Period 1: regular application with planned application errors | EXPERIMENTAL | - |
| Extended Period 2: regular application with planned application errors | EXPERIMENTAL | - |
| Norelgestromin low dose 2.43mg 28/0 regimen non-Obese | EXPERIMENTAL | - |
| Norelgestromin mid dose 3.64mg 28/0 regimen non-Obese | EXPERIMENTAL | - |
| Norelgestromin high dose 4.86mg 28/0 regimen non-Obese | EXPERIMENTAL | - |
| Norelgestromin high dose 4.86mg 21/7 regimen non-Obese | EXPERIMENTAL | - |
| Norelgestromin mid dose 3.64mg 28/0 regimen Obese | EXPERIMENTAL | - |
| Norelgestromin high dose 4.86mg 28/0 regimen Obese | EXPERIMENTAL | - |
| Norelgestromin high dose 4.86mg 21/7 regimen Obese | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) | DRUG | MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) |
| MR-130A-01 Transdermal patch | DRUG | MR-130A-01 transdermal patch, containing 2.43 mg Norelgestromin, will be worn 28 days per cycle with no patch free period. |
Inclusion Criteria: * 1\. Healthy, post-menarcheal and premenopausal women of age 18 to 35 years (inclusive) at screening examination. 2\. BMI ≥18.0 kg/m2 at screening examination. 3. Participants must be in good physical and mental health as determined by vital signs, medical history, and physi...
130A-01 patch is an investigational contraceptive transdermal patch being developed for contraception. It is a small molecule product in Phase 2 clinical development. The patch is designed for use in women aged 18 years and older, and it is being studied as a method of birth control.
130A-01 patch is being developed by Viatris Inc., a pharmaceutical company traded on the NASDAQ under the ticker symbol VTRS. The company is conducting clinical trials to evaluate the safety and efficacy of this contraceptive patch.
130A-01 patch is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness for contraception.
130A-01 patch has one completed Phase 2 clinical trial, identified as NCT06048536, titled 'Dose-finding Study of MR-130A-01 Contraceptive Transdermal Patch'. This randomized, controlled study enrolled 168 healthy female participants in Germany, aged 18 years and older.
Yes, 130A-01 patch is also known as MR-130A-01. The clinical trial NCT06048536 refers to the drug as MR-130A-01, indicating that these names are used interchangeably for the same investigational contraceptive transdermal patch.
130A-01 patch is a small molecule contraceptive delivered through a transdermal patch. The specific molecular target or mechanism of action has not been disclosed in available information. The patch is designed to provide contraception when applied to the skin.